Business Context and Reporting Period
This Form 8-K filing by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) covers the date of January 24, 2017. The report details the entry into a material definitive agreement with DuPuy Synthes Sales, Inc. regarding the commercialization of Pacira's lead product, EXPAREL.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new commercial agreement rather than financial performance data.
Material Changes and Agreement Details
- Agreement Type: Five-year Co-Promotion Agreement for the exclusive distribution, promotion, and sale of EXPAREL for operating room use in orthopedic and spine surgeries in the United States.
- Counterparty: DuPuy Synthes Sales, Inc. (DuPuy).
- Term: Commenced January 24, 2017, ending December 31, 2021, with options to extend in 12-month increments.
- Compensation: DuPuy is entitled to annual royalty payments on sales, subject to conditions and adjustments.
- Termination: Mutual termination rights exist; however, neither party may terminate without cause within the first three years of the effective date.
Outlook, Risks, and Management Commentary
The agreement expands Pacira's market reach by leveraging DuPuy's distribution network for orthopedic and spine procedures. The filing notes that the agreement includes customary representations, warranties, and mutual indemnification obligations. DuPuy is subject to compliance with applicable laws and Pacira's policies. The full text of the agreement is scheduled to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2017.
Key Facts for Investor Verification
- Verify the specific royalty rates and payment structures detailed in the full Co-Promotion Agreement.
- Confirm the projected sales volume of EXPAREL in the orthopedic and spine segments under DuPuy's distribution.
- Review the upcoming Form 10-Q (Q1 2017) for the complete legal text of the agreement.
- Assess the impact of this exclusive arrangement on Pacira's direct sales force and existing distribution channels.